The synthesis of tissue factor pathway inhibitor (TFPI) was investigated in cloned human synovial cells and human chondrocytes. TFPI-specific DNA transcription products of these cells were isolated, and a full-length cDNA of about 1000 base pairs was amplified by reverse transcription and polymerase chain reaction. The amplified DNA was cloned into the vector pUC 18. The TFPI coding sequence was confirmed by double stranded sequencing and was identical with that previously published for human TFPI coding nucleotide sequence frorn human placental cDNA (1).
Introduction
(i) TFPI inhibits factor Xa and (ii) factor Xa/TFPI complex inhibits factor VH/tissue factor complex by forming Tissue factor pathway inhibitor (TFPI) is a physiplogi-a quaternary complex (3, 4). cally important factor in blood coagylatiön (1), consisting of three tandem Kunitz-type inhibitor domains. Domain I has been identified äs the binding site of factor j^ctca^ EC 3 4 2 1 6 Vlla/tissue factor 1 ). The second domain binds factor Factor Vlla EC 3. 4 TFP1 has been detected in endothelial cells and megakaryocytes. Only minimal amounts are present in mononuclear cells, and none has been detected in hepatocytes (5) . However, the expression of TFPI in cells of the synovial System has not hitherto been investigated.
It has been suggested that TFPI may be an important factor for bleeding in haemophiliacs (6) and it has been shown that blocking of TFPI normalises the dilute tissue factor clotting time, which is prolonged in plasma of haemophiliacs (7) . Inhibition of coagulation in the synovial System has been assumed in haemophilia. In this disease, the alternative factor X activation is not possible, due to factor VIII or IX deficiency. Haemophilic patients suffer spontaneous and often massive bleeding, 90% of which occurs in the joints. The predilection of joint bleeding in haemophiliacs led us to investigate the expression of tissue factor pathway inhibitor in human chondrocytes and human synovial cells.
Materials and Methods

Materials
Agarose was purchased frorn Biozyme Diagnostic, Hameln. Dulbecco's Eagle medium, Harn 9 s F-12 medium, foetal calf serum, human factor VII, human factor X, N-benzoyl-Ile-Glu-Gly-Arg-/>-nitroanilide (S-2222), CsCl and antibiotic and antimycotic solution were obtained from Sigma, Deisendorf. Recombinant tissue factor was from Baxter, Unterschlei heim and AmpliTaq DNA Polymerase from Perkin Eimer Cetus, Vaterstetten. Reverse transcriptase was obtained from BRL, Eggenstein and DNA Standard and dNTP were from Pharmacia, Freiburg. Polycarbonate filters were purchased from Nunc, Wiesbaden. All chemicals used were of analytical grade or the highest grade commercially available. phate (9) , hyaluronan) and markers specific for macrophages (neopterin, sCD14) (data not shown).
Preparalion of human chondrocyte cell cultures
Chondrocyte cultures were prepared from pieces of human knee joints. The pieces were collected in Harn 's F-12 medium, which was enriched with 10 g/l antibiotic solution (see section cell culture). Cartilage slices were digested for 90 min at 37 °C with 0.01 g/l pronase in 100 ml F-12 medium containing 5 g/l foetal b vine serum, followed by 0.3 g/l bacterial collagenase 1 ) in the same med ium for 180 min at 37 °C. The final digest was centrifuged at 900s" 1 for 10 min. The cell pellet was washed three times in serum-free medium. The cells were collected by passing the suspension through a Nitex nylon filter (mesh width 60 μιη), then resuspended in serum-containing medium. Cell viability was determined by trypan blue dye exclusion. The cells were cultivated over four days in F-12 medium in tissue culture dishes precoated with agarose to avoid cell attachment. The surviving chondrocytes were collected again on a nylon filter and examined under a light microscope for their spherical morphology.
Ribonucleic acid Isolation
The total amount of cellular RNA was isolated by CsCl gradient centrifugation (11) . Cells (lO 8 in 10 ml cell culture medium) were centrifiiged for 10 min at 900 s" 1 and the pellet was washed with 10ml buffer (0.14 mol/1 NaCl, 0.0027 mol/1 KC1, 0.008 mol/1 Na 2 HPO 4 , 0.0015 mol/1 KH 2 PO 4 , 0.0005 mol/1 MgCl 2 , 0.0009 mol/1 CaCl 2 , l g/l glucose, pH 7.3). The pellet was resuspended in l .6 ml guanidinium thiocyanate solution (0.025 mol/1 Tris/HCl, 4 mol/1 guanidinium thiocyanate, 0.5 g/l N-lauroylsarcosine, 0.025 mol/1 EDTA, 0.1 mol/1 -mercaptoethanol, pH 7.6). The solution was aspirated 10 times through a small syringe needle tp shear chromosomal DNA. After the addition of CsCl solution (5.7 mol/1 CsCl, 0.01 mol/1 EDTA, pH 7.0) to a final volume of 4.5 ml, the solution was centrifiiged for 18 hours at 150000s" 1 . The supernatant was discarded and the RNA pellet was dissolved in 100 μΐ 0.01 mol/1 Tris, 0.001 mol/1 EDTA, pH 7.4 (10). After phenol extraction and precipitation with ethanol (12) the isolated RNA was used for cDNA synthesis by reverse transcription.
Methods
Cell culture
Human chondrocytes and human synovial cells were obtained from tissue pieces of the knee-joint capsule during meniscotomy. The cells were isolated (8) and cultivated in Dulbecco's modified Eagle medium supplemented with 100 g/l heat inactivated foetal calf serum and 10 g/l antibiotic and antimycotic solution (containing penicillin (lO 5 U/l), streptomycin (100 mg/1) and amphotericin B (2.5 mg/1)) in a humidified incubator with 5% CO 2 . Cells (lO 8 ) were incubated for 72 hours in 9 ml medium. The medium was collected and the inhibitory activity of TFPI was determined.
Cloning synovial cells
The detailed techniques for cloning and characterising synovial cells will be published elsewhere (10) . In brief, to obtain homogeneous cell cultures of human synovial cells 100 μΐ of a diluted cell solution were transferred to a well of a microtitre plate and examined under a light microscope. Only wells containing a single cell were used for further investigations. Cell culture medium was ' added and a polycarbonate filter (pore size 0.1 μηι) with an attached monolayer of the same cell preparation was cocultivated. The cells had no direct contact with the single cell and were necessary for optimal growth of the isolated cell. The resulting human synovial cell clones were incubated in cell culture medium, and characterised by fibroblast-specific cell markers (chondroitin-6-sul-
Reverse transcription
Isolated RNA (0.1-5 μg) and 7 pm l oligo d(T) 12 _ 18 primer were incubated at 37 °C for 90 min with 10 umol dNTP and 200 U reverse tr nscriptase 1 ) (12) . The synthesised cDNA/RNA hybrids were irnmediately used for the polyraerase chain reaction.
Tissue factor pathway inhibitor cDNA synthesis
A full-length cDNA was synthesised using the polymerase chain reaction (13) . The following primers were used (5):
S'-TACTGCAGCGCCAAGAACTTTCATCAGAGA-^1;
primer II:
S'-GCGAATTCGCTAATGTTACATTGCTATAAC-S'
The cDNA complementary sequences of the primers are in bold type. Primer I contains a Pst I l ) restriction site and primer II an Eco RI ! ) site.
Deoxyribonucleic acid sequencing
The endonuclease restriction sites, Pst I and Eco Rl, of the generated araplification product were used for cloning into the vector " pUC 18. The TFPI coding DNA was C9nfirrned by double stranded sequencing (14) in both upstreara an^downstreani orientation.
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Determination of tissue factor pathway inhibitor activity
The inhibitory activity of TFPI was measured by a modified chromogenic Substrate assay based on the ability to inhibit factor X activation by factor Vlla/tissue factor complex (15) (16) (17) . Factor VII (100 μΐ, 12.5 U/l) and 100 μΐ recombinant tissue factor (dilution: 1/20) were added to 100 μΐ 0.075 mol/1 CaCl 2 and 100 μΐ factor X (25 U/l). After 10 min incubation, 100 μΐ cell culture medium (l : 5 diluted in 0.05 mol/1 Tris/HCl, 0.1 mol/1 NaCl, pH 8.0) were added and, after additional incubation for 10 min, virtually all of factor X (400 U/l) was added in a volume of 100 μΐ. After incubation for 10 min the chromogenic reaction was started by the addition of 100 μΐ of the synthetic Substrate N-benzoyl-IleGlu-Gly-Arg-jp-nitroanilide (0.0027 mol/1) and the absorbance was measured at 405 nm. All samples were heat inactivated for 10 min at 56 °C before testing.
Inhibition ofTFPI activity by anti-TFPI antibody
In the chromogenic Substrate assay for factor Xa activity the inhibitory activity of tissue factor pathway inhibitor was suppressed by a monospecific goat anti-TFPI antibody. The antibody was obtained by immunisation of a goat with recombinant, two-domain TFPI frorn yeast (18) . Cell culture medium (100 μΐ, diluted l : 5 in 0.05 mol/1 Tris/HCl, 0.1 mol/1 NaCl, pH 8.0) was incubated with 100 ng anti-TFPI antibody for 30 min at room temperature. This dilution was used in the chromogenic Substrate assay s described above.
Results
Isolation of TFPI-specific RNA and synthesis ofTFPI cDNA TFPI-specific DNA transcription products were isolated from both human chondrocytes and human synovial cells, and a TFPI coding cDNA of about 1000 b se pairs was obtained by reverse transcription and polymerase chain reaction ( fig. 1 ). The gener ted TFPI cDNA was analysed by double stranded sequencing in both upstream and downstream orientation. No difference from the TFPI coding nucleotide sequence described for human endothelial cells was observed.
After the Isolation of the total amount of RNA, an unspecific cDNA synthesis was performed by reverse transcription using an oligo-d(T)g-i2 primer. The synthesised TFPI-specific RNA/cDNA hybrids were amplified by the polymerase chain reaction. The used primers hybridised in the non-coding region close to the TFPI coding sequence and gener ted the desired amplification product.
The polymerase chain reaction primers I and II contained single restriction sites (Pst l and Eco RI, respectively) for cloning the amplified DNA into the vector pUC 18. This vector was used for sequencing the amplified TFPI coding sequence.
Determination of the inhibitory activity of TFPI in cell culture medium
The inhibitory activity of TFPI in cell culture media from human chondrocytes and cloned human synovial cells was determined by measuring the Inhibition of factor X activation by factor Vlla/tissue factor complex, using a synthetic Substrate (S-2222). The inhibitory activity of TFPI in the medium of human synovial cells was 1080-1665 mU/10 8 cells (n = 5). In the medium of human chondrocytes the inhibitory activity was 630-720 mU/10 8 cells (n = 3).
Inhibition ofTFPI activity by a monospecific anti-TFPI-antibody Hundred ng monospecific anti-TFPI antibody, specific for the first two Kunitz domains of TFPI, quantitatively suppressed the inhibitory activity ofTFPI in cell culture media from human chondrocytes and human synovial cells. In the chromogenic Substrate assay, factor X activity was not infl enced by the addition of cell culture medium preincubated with anti-TFPI antibody ( fig. 2 ) thus identiiying the inhibitory activity in the medium s TFPI.
Disc ssion
The expression of tissue factor pathway inhibitor has so far only been described for endothelial cells and megakaryocytes. We investigated the synthesis ofTFPI in human synovial cells and in human chondrocytes. Our investigations showed that these cells also synthesise TFPIrspecific DNA transcription products and express TFPI in the cell culture medium. The amidolysis of the synthetic Substrate, N-benzoyl-Ile^GhnGly-Arg-/?-nitroanilide, by factor Xa in the chromogenic assay was monitored by measuring the absorbance at 405 nm. Factor Xa activity was measured in the presence of (-A-) and without (-p-) cell culture medium (20 ) . Factor Xa activity was not influenced by the addition of cell culture medium preincubated with 100 ng anti-TFPI antibody (-^-).
The synthesis of tissue factor pathway inhibitor in human synovial cells and human chondrocytes seems to be part of an important regulation process in the synovial System, which maintains a balance between fibrinolytic and clotting reactions during minimal bleeding, and avoids inadequate fibrin deposition on the cartiläge süf-face of the joint.
Coagulation is initiated by tissue factor (thromboplastin) which is expressed in fibroblasts, macrophages and endothelial cells (19) , and results in activation of the extrinsic pathway of coagulation. Synovial cells are supposed to lack tissue factor (20) which is necessary for the extrinsic pathway of factor X activation. This hypothesis has served äs an explanation for the special joint bleeding in haemophiliacs. However, it was shown that monocytes, which are present in the synovial membrane, are able to produce tissue factor (20, 21) and other procoagulant and anticoagulant molecules (22) . Whether synovial cells type A (23), which are probably derived from monocytes, also synthesize tissue factor is not known.
In haemophiliacs, factor Xa generation depends exclusively on the factor Vlla/tissue factor pathway, since factor VIII or factor IX are deficient. This deficieiicy prevents an alternative activatioh of factor X. Thus, an Inhibition of factor X activation by TFPI results in an additional decrease in the coagulation process in haemophiliacs. It has been shown that the addition of TFPI in a thromboplastin assay prolongs the coagulation time in normal plasma, while the addition of an inhibitory antibody against TFPI shortens it (17, 18). Furthermore, anti-TFPI antibody normalised the coagulation time in haemophilic plasma in a dilute thromboplastin assay (17) . Therefore, the presence of TFPI in the synovial System would seem to be the reason why joints are the predilected site of bleeding in haemophiliacs. Ninety percent of haemophilic bleeding occurs spontaneously in the joints. Liberated plasma TFPI, in addition to TFPI from synovial cells, represents an anticoagulant pöten-tial which in haemophiliacs completely irihibits haemostasis and leads to massive bleeding in the joints, even when only small vessels are injured.
Further investigations will give mofe Information on the physiological fiinction of TFPI in the synovial System and on the influence of inflammatory mediators such äs interleukin l, tumour necrosis factor and bacterial lipopolysaccharides on the cellulär expression of TFPI in the synovium. These mediators are known to shift the haemostatic balance in favor of procoagulant activities in endothelial cells (24) .
